Judy H. Chiao, MD, Chief Medical Officer
Dr. Chiao joined Epigenetix in June 2021 bringing 20 years of experience in clinical development of new oncology drugs. As a medical oncologist, she has designed and conducted clinical trials in advanced solid tumors and hematological malignancies in collaboration with leading disease experts at major medical centers in USA and Europe. Previously, she was Vice President of Clinical Development and Regulatory Affairs at Cyclacel Pharmaceuticals, Inc. where she led the clinical development of cyclin-dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitor, aurora kinase inhibitor and oral nucleoside analog. She oversaw filings of multiple investigational new drug applications (INDs), led interactions with regulatory agencies and successfully obtained a Special Protocol Assessment from the Food and Drug Administration (FDA) on a phase 3 registration study of front-line therapy in acute myeloid leukemia (AML). Dr. Chiao began her industry career at Aton Pharma, Inc., a wholly owned subsidiary of Merck & Co. Inc. Prior to Aton’s acquisition by Merck, she was responsible for leading the clinical development of Zolinza, an oral histone deacetylase (HDAC) inhibitor. Zolinza was the first HDAC inhibitor to receive FDA’s full approval for the treatment of cutaneous T-cell lymphoma. In addition to her clinical development experience, Dr. Chiao brings regulatory expertise and insights after serving as Senior Medical Reviewer in Division of Oncology Drug Products, Center for Drug Evaluation and Research, FDA. She was the agency’s primary reviewer of first-in-human studies in INDs and registration studies in New Drug Applications (NDAs). She presented FDA’s views on the NDAs of prostate cancer, melanoma, and adenomatous polyposis at the Oncology Drugs Advisory Committee (ODAC) meetings.
Dr. Chiao received her M.D. from Harvard Medical School. She completed an internship and residency in internal medicine at Columbia-Presbyterian Medical Center. She held a Research Fellowship in Molecular Pharmacology at Sloan Kettering Institute for Cancer Research, a Clinical Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center and has earned certifications in internal medicine and medical oncology. She holds a B.S. in Chemistry, summa cum laude, from Columbia University.